Compare ACNT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | NYXH |
|---|---|---|
| Founded | 1945 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.0M | 190.6M |
| IPO Year | 1995 | 2021 |
| Metric | ACNT | NYXH |
|---|---|---|
| Price | $12.79 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 125.5K | 56.7K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.72 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $97.32 |
| Revenue Next Year | N/A | $241.74 |
| P/E Ratio | $143.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.62 | $3.37 |
| 52 Week High | $17.92 | $11.87 |
| Indicator | ACNT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 20.15 | 28.09 |
| Support Level | $12.08 | N/A |
| Resistance Level | $13.06 | $5.02 |
| Average True Range (ATR) | 0.60 | 0.27 |
| MACD | -0.44 | -0.08 |
| Stochastic Oscillator | 5.81 | 1.47 |
Ascent Industries Co specializes in development, production, and distribution of specialty chemicals. The company produces specialty ingredients and products for the oil and gas, household, industrial and institutional, personal care, coatings, adhesive, sealants, elastomers, pulp and paper, textile, automotive, agricultural, water, treatment, and construction industries. The products of the company include: Surfactants, Defoamers, Flame Retardants, Emulsifiers, Lubricants, Plasticizers, Straight Esters and Others.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.